Osimertinib, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TREM
- 22 Jun 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2018.
- 24 Jul 2015 New trial record